Prefer to listen without the ads? Become a Ben Bikman Insider.
Tirzepatide has changed what many clinicians thought was possible in obesity and type 2 diabetes treatment. The amount of weight loss seen in some of these studies would have seemed unrealistic just a few years ago outside of bariatric surgery.
But despite all the attention these drugs are getting, I believe there is still a major misunderstanding about how they actually work.
Most people have been told that tirzepatide works by increasing insulin. While there is some truth to that under certain conditions, the published human evidence tells a more interesting — and more important — story.
In many cases, tirzepatide appears to improve metabolic health not by increasing the body’s insulin burden, but by reducing the body’s need for insulin in the first place.
What Tirzepatide Actually Is
Tirzepatide is a medication that mimics two gut hormones called incretins:
- GLP-1
- GIP
These hormones are released after eating and help regulate blood sugar, appetite, digestion, and energy balance.
Most earlier medications focused only on GLP-1. Tirzepatide is different because it activates both GLP-1 and GIP receptors simultaneously, which appears to produce even greater metabolic effects.
The Insulin Narrative Falls Apart
The common explanation is that tirzepatide lowers blood sugar because it stimulates the pancreas to release more insulin.
However, when you examine the human clinical data closely, that explanation becomes difficult to support.
Studies consistently show that people taking tirzepatide often experience:
- Lower fasting insulin levels
- Improved insulin sensitivity
- Better glucose control with less insulin exposure
- Reduced insulin requirements overall
That matters because fasting hyperinsulinemia is one of the clearest markers of insulin resistance and metabolic dysfunction.
In other words, the body is becoming more responsive to insulin again. The pancreas is not simply being forced to work harder.
Where the Weight Loss Really Comes From
The dominant mechanism behind tirzepatide’s weight loss appears to be appetite regulation.
The medication acts on appetite centers in the brain while also slowing stomach emptying. Together, these effects:
- Reduce hunger
- Increase fullness
- Lower cravings
- Help people feel satisfied with less food
Over time, people naturally eat fewer calories without relying entirely on willpower.
There is no metabolic magic here. The weight loss is substantial because food intake declines substantially.
The GIP Paradox
One of the most fascinating aspects of tirzepatide is the role of GIP.
For years, researchers believed blocking GIP signaling might help treat obesity because animal studies showed weight loss when the receptor was inhibited.
Yet tirzepatide activates the GIP receptor and still produces profound weight loss.
At this point, we still do not fully understand why.
The most likely explanation is that GIP behaves differently in different tissues, particularly within the brain’s appetite-regulating centers. But this remains an active area of research and one that will likely teach us much more about metabolic regulation in the years ahead.
An Important Distinction
One of the most important findings from these studies is that weight regain commonly occurs when the medication is stopped.
That is exactly what we would expect if the drug is primarily suppressing appetite while it remains in the bloodstream.
Tirzepatide is not permanently resetting metabolism. It is overriding appetite signals while treatment continues.
That does not diminish the clinical value of the drug. The improvements are real and meaningful. But it does remind us that the deeper question of why modern metabolism becomes dysregulated in the first place still remains.
The Bottom Line
Tirzepatide may be one of the most effective metabolic therapies we have ever seen, but the idea that it works simply by “raising insulin” is misleading.
The evidence suggests it works primarily by:
- Reducing appetite
- Slowing stomach emptying
- Improving insulin sensitivity
- Lowering the body’s overall insulin demand
Understanding that distinction changes how we think about obesity, insulin resistance, and metabolic disease altogether.